Product Description: T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC50 values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research[1].
Applications: Cancer-Kinase/protease
Formula: C21H18N8
References: [1]Iwai K, et al. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability. EMBO Mol Med. 2018 Jun;10(6):e8289.
CAS Number: 2407433-00-3
Molecular Weight: 382.42
Compound Purity: 99.64
Research Area: Cancer
Solubility: DMSO : 8.25 mg/mL (ultrasonic)
Target: Apoptosis;CDK;DYRK
Deutsch
English
